AbstractMammalian target of rapamycin (mTOR) inhibitors represent a new class of potential anticancer agents. The mTOR inhibitor, rapamycin, inhibited proliferation in three mantle cell lymphoma (MCL) cell lines and reduced cyclin D3 expression while cyclin D1 levels remained unchanged. This finding was confirmed in cells from a MCL patient.
Figures & Tables
Vol. 90 No. 10 (2005): October, 2005 : Comparative Studies
Ferrata Storti Foundation, Pavia, Italy
Statistics from Altmetric.com